Sophie Amsellem-Bosq

CMC and Manufacturing Lead Advisor

Dr. Amsellem-Bosq has more than 20 years of experience in cell and gene therapy across the entire value chain from discovery through clinical development and manufacturing, up to bedside. Sophie served as Global CAR-T Program Director at Servier (France), where she led the company’s allogenic CAR-T pipeline development strategy. She was Head of Cell and Gene Therapy Manufacturing Business Unit at Yposkesi (France) and held several multi-faceted roles at various leading institutions such as Gustave Roussy Cancer Centre, Ambroise Paré Hospital and INSERM. She holds a PharmD from University Paris XI, Châtenay-Malabry and a PhD in Blood Cell Biology from University Paris VII, Paris. Most recently, Sophie was the Chief Technical Officer at InnoSkel, a company pioneering the development of in vivo gene therapies for bone disorders